Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Atypical Endometrial Hyperplasia (GOG-167)
NCT00003179Phase 2Terminated
- Sponsor
- GOG Foundation
- Start
- Nov 1998
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of medroxyprogesterone acetate in Atypical endometrial hyperplasia (AEH) (3 arms), sponsored by GOG Foundation. Primary endpoints: Joint occurrence of atypical hyperplasia and adenocarcinoma and Histologic response rates at 3 months. Started Nov 1998; status: terminated.
02
Drugs
medroxyprogesterone acetate
03
Conditions
Atypical endometrial hyperplasia (AEH)
Beyond the preview
Go deeper on NCT00003179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003179.